Featured Publications
Myelin Oligodendrocyte Glycoprotein–Associated Disorders
Longbrake E. Myelin Oligodendrocyte Glycoprotein–Associated Disorders. CONTINUUM Lifelong Learning In Neurology 2022, 28: 1171-1193. PMID: 35938661, PMCID: PMC9523511, DOI: 10.1212/con.0000000000001127.Peer-Reviewed Original ResearchConceptsAcute disseminated encephalomyelitisClinical spectrumCentral nervous system autoimmune diseaseNatural historyFuture therapeutic trialsLarge cohort studyRecent case reportsDistinct clinical phenotypesDisseminated encephalomyelitisGlycoprotein autoantibodiesOptic neuritisCohort studyMost patientsRelapse patternsNeuromyelitis opticaTherapeutic trialsMultiple sclerosisAutoimmune diseasesCNS diseaseCase reportCNS diseasesAccurate diagnosisClinical phenotypeDiseaseDisordersPrior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination
Asashima H, Kim D, Wang K, Lele N, Buitrago-Pocasangre N, Lutz R, Cruz I, Raddassi K, Ruff W, Racke M, Wilson J, Givens T, Grifoni A, Weiskopf D, Sette A, Kleinstein S, Montgomery R, Shaw A, Li F, Fan R, Hafler D, Tomayko M, Longbrake E. Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination. JCI Insight 2023, 8: e168102. PMID: 37606046, PMCID: PMC10543713, DOI: 10.1172/jci.insight.168102.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 mRNA vaccinationB-cell-depleted patientsB-cell depletionAntibody responseMRNA vaccinationThird doseCell depletionT cellsClaude D. Pepper Older Americans Independence CenterB cellsNational Multiple Sclerosis SocietyAnti-CD20 antibodySpike-specific antibodiesMultiple Sclerosis SocietyLow cumulative exposureLogistic regression modelsImportant clinical needCD20 therapyCD20 treatmentMost patientsThird vaccineSerologic responseVaccine dosesMRNA vaccinesVaccination strategies
2018
Effectiveness of alternative dose fingolimod for multiple sclerosis
Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, Berkovich R, Ge L, Bacon TE, Kister I. Effectiveness of alternative dose fingolimod for multiple sclerosis. Neurology Clinical Practice 2018, 8: 102-107. PMID: 29708225, PMCID: PMC5914753, DOI: 10.1212/cpj.0000000000000434.Peer-Reviewed Original ResearchProportion of patientsDaily doseMultiple sclerosisAlternate doseAdverse eventsDisease activityProfound lymphopeniaContrast-enhancing MRI lesionsAlternate dosingLiver function abnormalitiesClass IV evidenceDaily oral medicationContrast-enhancing lesionsBetter disease controlBreakthrough diseaseMRI lesionsRadiologic outcomesFunction abnormalitiesMost patientsOral medicationsRelapse rateFrequent dosingObservational studyFingolimodHigh risk